Calliditas Therapeutics AB (CALT)
21.63
-0.40
(-1.82%)
USD |
NASDAQ |
May 17, 16:00
21.63
0.00 (0.00%)
After-Hours: 20:00
Calliditas Therapeutics Total Liabilities (Quarterly): 151.43M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 151.43M |
September 30, 2023 | 115.39M |
June 30, 2023 | 110.94M |
December 31, 2022 | 113.86M |
September 30, 2022 | 71.13M |
June 30, 2022 | 72.15M |
March 31, 2022 | 51.24M |
December 31, 2021 | 49.92M |
September 30, 2021 | 54.38M |
June 30, 2021 | 30.62M |
March 31, 2021 | 29.20M |
December 31, 2020 | 25.35M |
Date | Value |
---|---|
September 30, 2020 | 7.071M |
June 30, 2020 | 6.628M |
March 31, 2020 | 5.957M |
December 31, 2019 | 6.114M |
September 30, 2019 | 3.156M |
June 30, 2019 | 5.120M |
March 31, 2019 | 3.184M |
December 31, 2018 | 3.368M |
September 30, 2018 | 3.181M |
June 30, 2018 | 6.570M |
March 31, 2018 | 3.848M |
December 31, 2017 | 3.560M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.156M
Minimum
Sep 2019
151.43M
Maximum
Dec 2023
50.54M
Average
40.27M
Median
Total Liabilities (Quarterly) Benchmarks
DBV Technologies SA | 34.24M |
Cellectis SA | 249.58M |
Adaptimmune Therapeutics PLC | 243.10M |
Akari Therapeutics PLC | 4.584M |
Biodexa Pharmaceuticals Plc | 7.470M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 184.69M |
Shareholders Equity (Quarterly) | 33.26M |
Debt to Equity Ratio | 2.806 |
Current Ratio | 3.132 |
Net Debt Paydown Yield | -1.46% |